Quick Takeaways
- TCG Crossover GP II, LLC filed SCHEDULE 13G/A for Nektar Therapeutics Common Stock, par value $0.0001 per share (NKTR).
- Disclosed ownership: 9.3%.
- Date of event: 30 Jun 2025.
TCG Crossover GP II, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Nektar Therapeutics Common Stock, par value $0.0001 per share (NKTR)
- Filing Manager
- TCG Crossover GP II, LLC
- Reporting Manager
- TCG Crossover GP II, LLC
- Symbol
- NKTR
- Shares outstanding
- 20,788,527 shares
- Disclosed Ownership
- 1,933,333 shares
- Ownership
- 9.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 16:14:00 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"TCG Crossover GP II, LLC disclosed 9.3% ownership in Nektar Therapeutics Common Stock, par value $0.0001 per share (NKTR) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 16:14.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 9.3% | 1,933,333 | 0 | 1,933,333 | /s/ Craig Skaling | Craig Skaling, Authorized Signatory | |
| TCG Crossover Fund II, L.P. | 9.3% | 1,933,333 | 0 | 1,933,333 | /s/ Craig Skaling | Craig Skaling, Authorized Signatory | |
| Chen Yu | 9.3% | 1,933,333 | 0 | 1,933,333 | /s/ Craig Skaling | Craig Skaling, as Attorney-in-Fact for Chen Yu |